Page contents Key factsDecisionRelated medicine informationTopicsKey facts Invented name ForsteoForsteo Active Substance teriparatide Therapeutic area Endocrinology-Gynaecology-Fertility-Metabolism Decision number P/189/2011 PIP number EMEA-001135-PIP01-11 Pharmaceutical form(s) Solution for injection in pre-filled penTransdermal system Condition(s) / indication(s) Treatment of fracturesTreatment of osteoporosis Route(s) of administration Subcutaneous useTransdermal use Contact for public enquiries Eli Lilly & Company LimitedE-mail: eu_paediatric@lilly.com Tel. +44 (0)1276 483000 Decision type W: decision granting a waiver in all age groups for all conditions or indications Decision date 02/08/2011DecisionP/189/2011: EMA decision of 2 August 2011 on the granting of a product specific waiver for teriparatide (Forsteo), (EMEA-001135-PIP01-11)AdoptedReference Number: EMA/507484/2011 English (EN) (73.04 KB - PDF)First published: 13/09/2011Last updated: 13/09/2011ViewRelated medicine informationForsteoTopicsPaediatricsShare this page